Anti-inflammatory therapy in the prevention of cardiovascular disease
Prof. Libby discusses IL-1β as a target for atherosclerosis therapy, a strategy that was evaluated in the CANTOS trial, which tested the monoclonal antibody canakinumab.
Video navigation menu
- Can inflammation biology in atherosclerosis be translated to the clinic? 00:55
- IL-1β as a target for atherosclerosis therapy 01:38
- Clonal hematopoiesis: A potent novel CV risk factor 03:25
- CANTOS: trial to address residual risk in secondary prevention 06:18
- CANTOS: primary and secondary outcomes 07:41
- CANTOS and incident cancer 08:43
This educational video aims to provide guidance and perspectives on the implications of the CANTOS trial addressing inflammation in CVD. This expert view may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Prof. Peter Libby is Mallinckrodt Professor of Medicine, Harvard Medical School; Senior Physician, Brigham and Women's Hospital, Boston, MA, USA
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.